研发管线
Programs Indication Rights Discovery IND Enabling Phase 1 Phase 2
Peripheral
SSAO
NASH
OA Pain
Fully owned
Liver targeting
THRβ
NASH
Dyslipidemia
Fully owned
SM GLP-1 T2D
Obesity
NASH
Fully owned
Exploratory
Projects
Immune or
Metabolic
indications
Fully owned except
one partnership
research with MNC

SSAO inhibitor

SSAO, also known as VAP-1, is a dualfunction protein with adhesive and enzymatic properties. .. SSAO can facilitate the recruitment and migration of inflammatory cells, induce oxidative stress and promote fibrosis. SSAO is elevated in NAFLD patients and associated with disease severity and progression. Knocking out SSAO attenuates steatohepatitis progression in several NASH models. Therefore, SSAO inhibitors have a great potential to be a new treatment modality for nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
As a peripheral restricted potent SSAO inhibitor with high selectivity and excellent safety profile. It has demonstrated therapeutic potential for NASH in STAM NASH model.

×

Thyroid hormone receptor agonist

Thyroid hormone receptor (THR) belongs to nuclear hormone receptor family. There are two major subtypes of THR, alpha(α) and beta(β). THRα is mainly expressed in heart, brain and bone while THRβ is present mainly in the liver, kidneys, pituitary gland and brain. Based on literature, most of unwanted effects (such as heart, bone etc.) of THR comes from activation of THRα while the beneficial effect of lipid lowering comes from THRβ [1,2]. Therefore, there has been a long history of developing THRβ selective agonists for treating dyslipidemia. Currently, there are two THRβ agonists in clinical trials: Resmetirom and VK2809. Both of them are not only selective for THRβ over THRα but also liver-targeting although through different mechanisms. Eccogene is dedicated to developing a THRβ agonist which has the potential to be best in class.
Ref
1. Delitala AP, Delitala G, Sioni P, Fanciulli G. Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future. Curr Med Res Opin. 2017 Nov;33(11):1985-1993. 2. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009 Apr;8(4):308-20.

×

×

Undisclosed MOA

甲状腺激素(Thyroid Hormone)是由甲状腺上皮细胞分泌的物质,在神经发育,能量代谢等众多生理过程的调节中起关键作用。甲状腺激素水平通过涉及下丘脑分泌的促甲状腺激素释放激素(TRH)和垂体分泌的促甲状腺激素(TSH)的负反馈机制得到严格控制,这个过程通常被称为下丘脑-垂体轴。

×

×

Undisclosed MOA

甲状腺激素(Thyroid Hormone)是由甲状腺上皮细胞分泌的物质,在神经发育,能量代谢等众多生理过程的调节中起关键作用。甲状腺激素水平通过涉及下丘脑分泌的促甲状腺激素释放激素(TRH)和垂体分泌的促甲状腺激素(TSH)的负反馈机制得到严格控制,这个过程通常被称为下丘脑-垂体轴。

×

×

Undisclosed MOA

甲状腺激素(Thyroid Hormone)是由甲状腺上皮细胞分泌的物质,在神经发育,能量代谢等众多生理过程的调节中起关键作用。甲状腺激素水平通过涉及下丘脑分泌的促甲状腺激素释放激素(TRH)和垂体分泌的促甲状腺激素(TSH)的负反馈机制得到严格控制,这个过程通常被称为下丘脑-垂体轴。

×

×

Immuno- metabolism

甲状腺激素(Thyroid Hormone)是由甲状腺上皮细胞分泌的物质,在神经发育,能量代谢等众多生理过程的调节中起关键作用。甲状腺激素水平通过涉及下丘脑分泌的促甲状腺激素释放激素(TRH)和垂体分泌的促甲状腺激素(TSH)的负反馈机制得到严格控制,这个过程通常被称为下丘脑-垂体轴。

×

×

Ligand ID Platform

甲状腺激素(Thyroid Hormone)是由甲状腺上皮细胞分泌的物质,在神经发育,能量代谢等众多生理过程的调节中起关键作用。甲状腺激素水平通过涉及下丘脑分泌的促甲状腺激素释放激素(TRH)和垂体分泌的促甲状腺激素(TSH)的负反馈机制得到严格控制,这个过程通常被称为下丘脑-垂体轴。

×

×